-
Innovent Biologics Reports 46.3% YOY Revenue Growth and Expands Portfolio with New Approvals and NDAs
•
Innovent Biologics, Inc., a leading biopharmaceutical company based in China and listed on the Hong Kong Stock Exchange (HKG: 1801), has announced its interim results for 2024 along with significant business updates. The company reported a robust year-over-year (YOY) growth in total revenue, which stood at RMB 3,952.3 million, marking…
-
Tigermed Partners with Beijing Government to Open North Headquarters, Expanding Collaboration in Biotech
•
Tigermed, a prominent Contract Research Organization (CRO) with a presence in both Shenzhen (SHE: 300347) and Hong Kong (HKG: 3347) stock exchanges, has forged a strategic partnership with the Beijing government. This collaboration is marked by the inauguration of the company’s North Headquarters in the capital city. Under this partnership,…
-
Luye Pharma Group’s 2024H1 Revenue and Net Profits Surge, Driven by Oncology and CNS Therapy Revenues
•
Luye Pharma Group, a China-based pharmaceutical company listed in Hong Kong (HKG: 2186), has reported its financial results for the first half of 2024. The company recorded revenues of RMB 3.0746 billion, marking a 6% increase year-on-year (YOY), and a significant surge in net profits, which rose by 201% YOY…
-
Asieris Pharmaceuticals Reports Explosive 103,397.96% YOY Revenue Growth in 2024H1 Financial Report
•
Asieris Pharmaceuticals, a China-based urogenital cancer specialist listed on the Shanghai Stock Exchange (SHA: 688176), has reported a staggering year-on-year (YOY) increase of 103,397.96% in its 2024H1 financial report, with revenues reaching RMB 80.4934 million. The second quarter of the year saw even more impressive growth, achieving RMB 56.1739 million,…
-
Online Pharmacy Service Drives Jianke.com’s Revenue Growth in H1 2024 Amid Diverse Business Segments
•
Jianke.com, a China-based smart healthcare service platform, has unveiled its financial report for the first half of 2024. The company recorded a modest year-on-year (YOY) increase in revenue, reaching RMB 1.323 billion, which is a 2.5% uptick. More impressively, the adjusted net profit saw a substantial surge of 395.0% YOY,…
-
Jiangxi Jemincare Secures First Generic Approval for GSK’s Requip in China
•
Jiangxi Jemincare Group, based in China, has received marketing approval from the National Medical Products Administration (NMPA) for its generic version of GSK’s Requip (ropinirole), marking the first generic approval for this medication in China. The drug is indicated for the treatment of Parkinson’s disease (PD) and PD with non-motor…
-
AstraZeneca to Invest $135 Million in Swedish Biomanufacturing Facility Expansion
•
AstraZeneca (NASDAQ: AZN, LON: AZN) , the UK-based biopharmaceutical leader, has announced a plan to invest $135 million in its biopharmaceutical manufacturing facility in Södertälje, Sweden. This marks the first significant investment in the Sweden Biomanufacturing Center since its inauguration in 2021. The funding will facilitate a 2,700 square meter…
-
Peijia Medical Secures Exclusive Rights to NowYon’s YonFlow Device in Greater China
•
Peijia Medical Ltd (HKG: 9996) has entered into a licensing agreement with NowYon Medical, securing exclusive rights as the agent for NowYon’s YonFlow blood flow guidance device in Greater China. This eight-year partnership marks a significant collaboration between the two Chinese firms. The YonFlow device, recognized as the world’s first…
